Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study.

Authors :: Hammel, Pascal
Ben Abdelghani, Meher
Roth, Gael
Ulusakarya, Ayhan
Ghiringhelli, François
Toullec, Clemence
Borg, Christophe
Hentic Dhome, Olivia
Trouilloud, Isabelle
Dahan, Laetitia
Hiret, Sandrine
Bouche, Olivier
Rinaldi, Yves
Blanc, Jean-Frédéric
De La Fouchardiere, Christelle
Neuzillet, Cindy
Kamal, Maud
Falcoz, Antoine
Turpin, Anthony
Guimbaud, Rosine
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p673-673, 117p
Publication Year :: 2024

Full Text Access

Tools